search
Back to results

RCT of Laser Therapy for GSM

Primary Purpose

Genitourinary Syndrome of Menopause

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Photothermal Non-ablative Erbium:YAG-laser
Fractional Microablative CO2-laser
Sponsored by
King's College Hospital NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Genitourinary Syndrome of Menopause

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Dryness and dyspareunia with moderate to severe intensity
  2. Vaginal Health Index <15
  3. Absence of menstruation for at least 12 months
  4. Recent Negative Pap-smear test (For women over 65 years old a negative pap smear test up to the age of 65).

Exclusion Criteria:

  1. Not willing to abstain from vaginal intercourse for one week following the laser-therapy
  2. Use of hormonal therapy within 6 months prior to study inclusion (systemic or local)
  3. Acute urinary tract infections (UTIs)
  4. History of a genital fistula, a thin recto-vaginal septum as determined by the investigator or history of a fourth-degree laceration during screening physical exam (e.g., perineal body)
  5. Active sexually transmitted disease upon vaginal exam (as determined by the investigator) that precludes treatment or any other vaginal infection
  6. Active or history of genital herpes
  7. Prolapse stages > II (according to the POP-Q system)
  8. History of radiotherapy for cervical or uterine cancer
  9. Medical condition that may interfere with participants' compliance to the protocol

Sites / Locations

  • Urogynaecology Department, King's College Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Fractional Microablative CO2-laser

Photothermal Non-ablative Erbium:YAG-laser

Arm Description

Outcomes

Primary Outcome Measures

Dryness - 10cm visual analogue scale
Dyspareunia- 10cm visual analogue scale
Itching- 10cm visual analogue scale
Burning- 10cm visual analogue scale
Dysuria- 10cm visual analogue scale
Frequency- 10cm visual analogue scale,
Urgency-10cm visual analogue scale
Urinary incontinence- 10cm visual analogue scale
Overall sexual satisfaction- Female sexual function index
Frequency- 3 day voiding diary
Urgency- 3 day voiding diary,
Urinary incontinence- 3 day voiding diary
Overall sexual satisfaction- 10cm visual analogue scale
Overall sexual satisfaction- frequency of sexual intercourse,

Secondary Outcome Measures

Quality of life- patients global impression of improvement questionnaire
Quality of life- day to day impact of vaginal ageing questionnaire
Quality of life- kings health questionnaire
Global impression of improvement- day to day impact of vaginal ageing questionnaire
Global impression of improvement- patients global impression of improvement questionnaire
Global impression of improvement- kings health questionnaire
Vaginal health index score- 5 components, elasticity, epithelial integrity, pH, moisture and fluid volume
Vaginal maturation value- vaginal smear stained with papanicolaou technique and VMI value is evaluated by defining the percentage of superficial, intermediate and paranasal epithelial cells on smear.
VMV = ((1x%superficial)+(0.5x%intermediate)+0xparabasal))

Full Information

First Posted
September 7, 2017
Last Updated
February 11, 2021
Sponsor
King's College Hospital NHS Trust
Collaborators
Alexandra Hospital, Athens, Greece
search

1. Study Identification

Unique Protocol Identification Number
NCT03288883
Brief Title
RCT of Laser Therapy for GSM
Official Title
Fractional Microablative CO2-laser Versus Photothermal Non-ablative Erbium:YAG-laser for the Management of Genitourinary Syndrome of Menopause: A Non-inferiority, Single-blind Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
February 11, 2021 (Actual)
Study Completion Date
February 11, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College Hospital NHS Trust
Collaborators
Alexandra Hospital, Athens, Greece

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the current study is to assess whether the CO2-laser results in superior alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective and subjective measurements of symptoms and clinical signs of GSM, between groups of postmenopausal women with GSM receiving treatment with CO2-laser or Er:YAG-laser.
Detailed Description
Genitourinary Syndrome of Menopause (GSM) is the new terminology for "vulvovaginal (VVA)". Although women may present with some or all of the clinical signs and symptoms, the most common symptom of VVA/GSM is vaginal dryness. Vaginal dryness appears early at menopause with a subsequent increase of prevalence as postmenopausal years' progresses and is associated with rising occurrence of lower urinary tract symptoms (LUTS). The therapeutic management of GSM includes lubricants and moisturizers as a first line therapy and low-dose vaginal estrogens as a second one, especially for women with a history of estrogen dependent cancer. However, lubricants and moisturizers can only be used for symptoms relief during sexual intercourse. They do not restore the local pathophysiology and they are inefficacious when LUTS are present. However, the quality of evidence is low or very-low when estrogens efficacy is compared to placebo, while the risk to the endometrial thickness with sustained vaginal estrogen use is not clear. Recently, intravaginal laser therapy has been proposed for the management of GSM. There are currently two lasers available. All available studies consistently suggest that both lasers (CO2-laser and Er:YAG-laser) are safe and have a high efficacy on alleviating vaginal dryness and dyspareunia, as well as restoring the local pathophysiology. Additionally, data regarding CO2-laser indicate LUTS improvement, as well as sexual function-satisfaction and quality of women's life. Relevant published data are not available for the Er:YAG-laser. Moreover, there is lack of studies comparing the 2 laser-technologies for the management of postmenopausal women with GSM. The aim of the current study is to assess whether the CO2-laser results in superior alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective and subjective measurements of symptoms and clinical signs of GSM, between groups of postmenopausal women with GSM receiving treatment with CO2-laser or Er:YAG-laser.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genitourinary Syndrome of Menopause

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fractional Microablative CO2-laser
Arm Type
Active Comparator
Arm Title
Photothermal Non-ablative Erbium:YAG-laser
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Photothermal Non-ablative Erbium:YAG-laser
Intervention Description
Laser treatment of the vagina for GSM
Intervention Type
Device
Intervention Name(s)
Fractional Microablative CO2-laser
Intervention Description
Laser treatment of the vagina for GSM
Primary Outcome Measure Information:
Title
Dryness - 10cm visual analogue scale
Time Frame
1 year
Title
Dyspareunia- 10cm visual analogue scale
Time Frame
1 year
Title
Itching- 10cm visual analogue scale
Time Frame
1 year
Title
Burning- 10cm visual analogue scale
Time Frame
1 year
Title
Dysuria- 10cm visual analogue scale
Time Frame
1 year
Title
Frequency- 10cm visual analogue scale,
Time Frame
1 year
Title
Urgency-10cm visual analogue scale
Time Frame
1 year
Title
Urinary incontinence- 10cm visual analogue scale
Time Frame
1 year
Title
Overall sexual satisfaction- Female sexual function index
Time Frame
1 year
Title
Frequency- 3 day voiding diary
Time Frame
1 year
Title
Urgency- 3 day voiding diary,
Time Frame
1 year
Title
Urinary incontinence- 3 day voiding diary
Time Frame
1 year
Title
Overall sexual satisfaction- 10cm visual analogue scale
Time Frame
1 year
Title
Overall sexual satisfaction- frequency of sexual intercourse,
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Quality of life- patients global impression of improvement questionnaire
Time Frame
1 year
Title
Quality of life- day to day impact of vaginal ageing questionnaire
Time Frame
1 year
Title
Quality of life- kings health questionnaire
Time Frame
1 year
Title
Global impression of improvement- day to day impact of vaginal ageing questionnaire
Time Frame
1 year
Title
Global impression of improvement- patients global impression of improvement questionnaire
Time Frame
1 year
Title
Global impression of improvement- kings health questionnaire
Time Frame
1 year
Title
Vaginal health index score- 5 components, elasticity, epithelial integrity, pH, moisture and fluid volume
Time Frame
1 year
Title
Vaginal maturation value- vaginal smear stained with papanicolaou technique and VMI value is evaluated by defining the percentage of superficial, intermediate and paranasal epithelial cells on smear.
Description
VMV = ((1x%superficial)+(0.5x%intermediate)+0xparabasal))
Time Frame
1 year

10. Eligibility

Sex
Female
Gender Based
Yes
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Dryness and dyspareunia with moderate to severe intensity Vaginal Health Index <15 Absence of menstruation for at least 12 months Recent Negative Pap-smear test (For women over 65 years old a negative pap smear test up to the age of 65). Exclusion Criteria: Not willing to abstain from vaginal intercourse for one week following the laser-therapy Use of hormonal therapy within 6 months prior to study inclusion (systemic or local) Acute urinary tract infections (UTIs) History of a genital fistula, a thin recto-vaginal septum as determined by the investigator or history of a fourth-degree laceration during screening physical exam (e.g., perineal body) Active sexually transmitted disease upon vaginal exam (as determined by the investigator) that precludes treatment or any other vaginal infection Active or history of genital herpes Prolapse stages > II (according to the POP-Q system) History of radiotherapy for cervical or uterine cancer Medical condition that may interfere with participants' compliance to the protocol
Facility Information:
Facility Name
Urogynaecology Department, King's College Hospital
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

RCT of Laser Therapy for GSM

We'll reach out to this number within 24 hrs